Bamlanivimab Injection

Bamlanivimab is a human immunoglobulin IgG variant monoclonal antibody. It was developed by Eli Lilly and Ab Cellera which has been authorized by FDA (November 2020) in an emergency for the use of mild to moderate COVID-19 in adults and pediatric patients or for those individuals who are at higher risk for progression to severe COVID-19. It is given by injection into the vein.

The Bamlanivimab and Etesivimab should be administered together, and they both are unapproved products. These are the following medical conditions at higher risk of COVID-19 who can use Bamlanivimab:

• Obesity or being overweight
• Pregnancy
• Chronic kidney disease
• Diabetes
• Immunosuppressive disease or immunosuppressive treatment
• Cardiovascular disease (including congenital heart disease) or hypertension
• Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis, and pulmonary hypertension)
• Sickle cell disease
• Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)
• Having a medical-related technological depend

It is an unapproved drug that is authorized for use under this emergency use authorization. It was originally derived from the blood of the first U.S patient who recovered from COVID-19.

This medicine is not for those patients who were hospitalized due to COVID-19. Also, it is not authorized to use in those patients who require oxygen therapy or those with increasing baseline oxygen flow rate.

Dosage: The dosage of Bamlanivimab for adults and pediatric patients with weight greater than 40 kgs is 700mg intravenous.

• Dosage for pediatric patients weighing less than 40kgs depends on their body weight.
• Patients with weight greater than 20 kgs and lesser than 40 kgs should take 350 mg IV.
• Patients with weight greater than 12 kgs and lesser than 20 kgs should take 350 mg IV.
• This medicine is not recommended for pregnant women.

This medicine is available as a solution. The patients who are treated with Bamlanivimab should isolate themselves and they should also use infection control measures like mask, social distancing, physical attachment with another individual, frequently hand wash and use sanitizer after touching anything.

Clinical Worsening after Bamlanivimab: After administration of Bamlanivimab the clinical worsening of covid 19 may include:

• Hypoxia
• Arrhythmia (Atrial Fibrillation, Sinus tachycardia)
• Altered mental status
• Increased Respiratory difficulty
• Symptoms of fever

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a General Physician before using this medicine.

• COVID-19

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a General Physician before using this medicine.

• Hypersensitivity

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a General Physician before using this medicine.

• Dizziness

• Chest Tightness

• Difficulty In Breathing

• Typhoid Fever

• Chills

• Headache

• Nausea Or Vomiting

• Confusion

• Sweating

• Muscle Pain

• Fast Heartbeat

• Itching Or Rash

• Bronchitis

• Allergic Skin Reaction

• Hypotension

• Pulmonary Arterial Hypertension (Pah)

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a General Physician before using this medicine.

• How long is the duration of effect?

  It is yet to be established. Kindly consult your doctor for more information.

• What is the onset of action?

  It is yet to be established. Kindly consult your doctor for more information.

• Are there any pregnancy warnings?

  Unknown or No information available. Kindly consult your doctor.

• Is it habit forming?

  No information available. Kindly consult your doctor.

• Are there any breast-feeding warnings?

  Unknown or No information available. Kindly consult your doctor.

• Is It safe with alcohol?

  No information available. Kindly consult your doctor.

• Is it safe to drive while on this medicine?

  No information available. Kindly consult your doctor.

• Does this affect kidney function?

  Available information implies that it does not impact the renal function of the patient on exposure with Bamlanivimab. However, consult your doctor before taking it.

• Does this affect liver function?

  Limited information available suggesting that it does not impact patients with mild hepatic impairment. However studies on the effect of Bamlanivimab on patients with moderate or severe hepatic disease are yet to be established. Kindly consult your doctor.

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a General Physician before using this medicine.

• Are there any missed dose instructions?

  If you miss a dose of Bamlanivimab, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.

• Are there any overdose instructions?

  Seek emergency medical treatment or contact the doctor in case of an overdose.

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a General Physician before using this medicine.

• India

• United States

• Japan

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a General Physician before using this medicine.

Bamlanivimab binds to the domain viz. receptor binding domain of the S protein at ACE2 binding site as an overlapping position. It binds with S protein and blocks the interaction of ACE2. It is not metabolized by cytochrome. Also blocks the entry of viruses into human beings.

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a General Physician before using this medicine.

Whenever you take more than one medicine, or mix it with certain foods or beverages, you"re at risk of a drug interaction.

test

• Interaction with Medicine

  Medicine

  • Interactions with concomitant renally excreted drugs that are CYP450 substrate, Inducers or inhibitors are unlikely.
  • It's not renally excreted or metabolized by CYP450 enzymes.

• Ques : What are the storage conditions required for Bamlanivimab?

  Ans :

  Storage: It is to be stored in a cool and dry place. Unopened vials should be kept in a refrigerator with temperature in between 2 °C to 8 °C (36 °F to 46 °F). Do not freeze, shake, or expose to direct light.

• Ques : Is there any specific warning for the patients consuming Bamlanivimab?

  Ans :

  Infusion related reactions: If you observe some sensitive reactions during fusion or up to 24 hours after fusion stop using it. It may be severe or life threatening.